ENN0403 clinical trials
How each study uses ENN0403 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ENN0403 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2024 | 2 |
Who runs them
Industry 3 · Other 0
EnnovaBio (3)
Studies
Open first, then newest update. How each study uses ENN0403 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Efficacy and Safety of ENN0403 in Patients At High Risk for Acute Kidney Injury Following Elective Cardiac SurgeryRecruitingPhase 2EnnovaBioNCT06632613Written as ENN0403 capsules, low dose
- A Phase 2 Study to Evaluate the Efficacy and Safety of ENN0403 in Subjects With DMECompletedPhase 2EnnovaBioNCT06708260Written as ENN0403, low dose
- A First-in-human Single Ascending Dose/Multiple Ascending Dose Study of ENN0403 in Healthy SubjectsCompletedPhase 1EnnovaBioNCT05506540Written as ENN0403 1mg